LLY
Another checkbox for Lilly
Eli Lilly’s oral GLP-1, Foundayo (orforglipron), picked up another positive data point: it was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease. That’s the kind of sentence that makes investors sit up a little straighter, because the GLP-1 race is basically a high-stakes game of “who can make people care about pills instead of injections.”
Why this matters
The headline here isn’t just that the drug looked decent. It’s that Lilly is trying to show its pill may have benefits that stretch beyond weight loss and blood sugar, which is exactly how you turn a promising obesity drug into a broader metabolic franchise.
For investors, that means:
- more evidence the pill could win share in a giant market
- another reminder that Lilly keeps stacking up data while competitors try to catch up
- a little extra confidence that the company’s GLP-1 machine still has momentum
The bigger race
GLP-1s are the pharmaceutical version of a blockbuster sequel: everyone knows the genre, but only a few studios can actually make the hit. Lilly already has a monster franchise with Zepbound and Mounjaro, and a successful oral option could make the story even juicier.
The catch? This is still about predicted risk, not a hard-outcomes trial proving fewer heart attacks or diabetes cases in real life. So yes, it’s encouraging — but not exactly the final boss fight.
Big picture: Lilly keeps reminding Wall Street that its GLP-1 pipeline isn’t just alive; it’s collecting trophies.